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Abstract 
Mammary glands, by the very nature of their post-natal development require dynamic 
cell interactions and high levels of cellular organization post-partum.  The gland can essentially 
be separated into two main compartments—the epithelial tissue and the supporting stromal fat 
pad.  Since a majority of breast cancers are of epithelial origin and rapid proliferation and 
apoptosis are typically associated with these cells, most cancer research has primarily focused on 
understanding the epithelial-component of tumorigenesis and tumor progression.  Recently, 
however, there has been increased interest in how the stroma communicates with the epithelia 
and how the tumor microenvironment might affect the behavior of the tumor itself.  Genetic 
manipulation of the stroma, and more specifically the fibroblasts, has remained difficult until the 
discovery of the fibroblast-specific protein 1 (FSP1) and the elucidation of the promoter 
controlling its expression.  Using the FSP1 promoter, a fibroblast-specific cre-recombinase was 
created to enable genetic manipulation of the stroma in vivo in order to study the importance of 
the microenvironment on tumor initiation and progression. 
 
Introduction 
Mammary glands, by the very nature of their post-natal development require dynamic 
cell interactions and high levels of cellular organization post-partum.  The gland can essentially 
be separated into two main compartments-the epithelial tissue and the supporting stromal fat pad.  
The component involved in the production and secretion of milk is the epithelial tissue.  It is 
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comprised of sac-like structures and lobules which are connected through a tree-like network of 
ducts responsible for funneling the milk to the nipple.  The stroma makes up the rest of the gland 
and consists of the adipocytes, fibroblasts, endothelial cells, macrophage, lymphocytes, B cells, 
T cells, nerve cells, and extracellular matrix surrounding and supporting the epithelial cells 
(Mueller and Rusenig, 2004) 
During puberty, cells in the terminal end buds rapidly proliferate and penetrate into the 
fat pad allowing the ductal tree to branch and elongate through the stroma from the main 
collecting ducts at the nipple.  These end buds disappear after duct elongation is complete.  With 
the onset of pregnancy the ducts undergo lateral branching, which ultimately terminates in the 
formation of acini structures, also called alveoli, for producing milk.  Each acinus consists of a 
single layer of highly polarized cells that form a sac-like structure containing the hollow lumen 
on the interior.  The epithelial cells are histologically distinct by the way they form rings or tubes 
through tight cell-cell junctions as well as their relatively large, cuboidal shape.  On the exterior, 
the epithelial cell layer is surrounded by a thin layer of myoepithelial cells which contain smooth 
muscle actin and contract to secrete the milk.  The basal lamina, or basement membrane, 
separates these two cell layers from the surrounding stroma.  Late in pregnancy, nearly all of the 
stroma volume is replaced by the expanded ductal tree and alveoli, which begin to lactate after 
birth.  After weaning, the process of involution begins and the alveoli regress as many of the 
epithelial cells undergo programmed cell death, otherwise known as apoptosis (Dunbar and 
Wysolmerski, 2001). In the mouse, a small number of these alveoli structures develop and then 
regress within the mammary gland every five days as a result of hormone production during its 
estrous cycle (Fata et al., 2001). 
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With these frequent episodes of proliferation and apoptosis, in addition to large scale 
changes associated with pregnancy, it is easy to imagine the potential danger for developing 
cancer should these cellular processes become deregulated.  Since a majority of breast cancers 
are of epithelial origin and rapid proliferation and apoptosis are typically associated with these 
cells, most cancer research has primarily focused on understanding the epithelial-component of 
tumorigenesis and tumor progression.  Recently, however, there has been increased interest in 
how the stroma communicates with the epithelia and how the tumor microenvironment might 
affect the behavior of the tumor itself.   
Studies elucidating just how important the stroma is in proper formation of the mammary 
gland played an important role in laying the foundation for this area of research.  It has been 
suggested that the response of the mammary gland to estrogen is mediated by the stroma and not 
the epithelia (Cunha et al., 1997).  The transplantation of mouse mammary epithelia into the 
submandibular salivary gland stroma results in what resembles a normal salivary gland; 
however, the epithelia still secrete the milk protein α-lactalbumin.  Thererfore, the stroma must 
have a very significant role in the processes that control the morphological development of the 
epithelial network of ducts but has no affect on the cytodifferentiation of the epithelial cells 
themselves.  The extracellular matrix could be part of the reason for this remarkable result.  
Epithelial branching in the salivary gland requires the extracellular matrix protein fibronectin 
which is secreted by fibroblasts (Sakai et al, 2003). 
The extracellular matrix consists of non-living macromolecules in the extracellular space 
such as fibrous and non-fibrous collagens, glycoproteins, and proteoglycans (Silberstein, 2001).  
All tissues are composed of cells and an extracellular matrix (ECM).  The components of the 
ECM are synthesized and secreted by various types of cells including epithelial cells, smooth 
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muscle cells, and fibroblasts.  Matrix metalloproteinases (MMPs), one type of the 
macromolecules comprising the ECM, have been linked to the loss of integrity of the 
microenvironment that can lead to tumors (Bissell & LaBarge, 2005; Sternlicht et al, 1999).  
Genetic equivalence is one of the main arguments for the significance of the microenvironment 
in tumorigenesis.  Nuclei from malignant cancer cells have been placed in enucleated oocytes 
and eventually used to produce chimeric mice.  The majority of tissues developed normally in 
these mice because the normal microenvironment was able to control the malignant nature of the 
cells (Bissell & LaBarge, 2005; Hochedlinger et al., 2004).  This suggests that some sort of 
activated microenvironment is necessary for the initiation and progression of cancer. 
A recent study hoping to reveal some of the genetic alterations that might lead to such an 
activated state analyzed genomic deletion of primary tumor sites from patients with invasive 
breast cancer and determined that there are nearly two fold more targets for genetic alterations in 
the stromal cells compared to the neighboring epithelial tumor cells (Fukino et al., 2004).  
Among these targets are the tumor suppressor genes p53 and PTEN, two of the more frequently 
mutated and/or delete genes in sporadic cancers.  The stromal alterations in most invasive breast 
carcinomas are marked by an increase in fibroblasts and a modified, collagenized ECM.  These 
carcinoma-associated fibroblasts (CAFs) are reported to express greater amounts of extracellular 
matrix molecules, various molecules that modulate the ECM, and many growth factors relative 
to fibroblasts found in normal mammary glands and have a decreased ability to suppress 
proliferation of pre-carcinoma epithelial cells (Sadlonova et al., 2005; Kunz-Schughart, 2002).    
Most ECM macromolecules were thought to serve a purely structural role in aiding cell adhesion 
and migration by providing a framework to act upon; however, when these molecules are 
cleaved by integrin-receptors, some have cryptic functions not expressed by their full length 
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counterparts such as activating signal transduction pathways similar to those activated by 
cytokines which have been recorded in the initiation and progression of cancer (Schor and Schor, 
2001; Juliano, 1996).  The upregulation of matrix metalloproteinases 1 and 9 (MMP1 and 
MMP9) which activate cell-surface and ECM-bound growth factors have been shown to 
correlate with malignancy, but this correlation was only found to be in the presence of stromal 
fibroblasts (Mueller et al., 2004; Borchers et al., 1997). 
Because fibroblast are known to lay down much of the scaffolding of the mammary gland 
including the basement membrane, along with their well-documented increase in secretion of 
many growth factors and extracellular molecules, the specific study of how genetic alterations in 
these cells affect tumorigenesis and tumor progression is a logical place to begin.  Fibroblasts are 
non-vascular, non-epithelial, and non-inflammatory cells.  They are the principal cellular 
component of the connective tissue and are largely responsible for its synthesis (Kalluri and 
Zeisberg, 2006).  Fibroblasts are ubiquitous and highly heterogeneous; they are as diverse as the 
locations in which they are found.  Fibroblasts are elongated cells which lack markers that 
indicate other cell lineages.  There are markers that indicate fibroblastic phenotype; however, 
none of them are exclusive to and expressed in all fibroblasts.  For example, vimentin is 
expressed in a wide variety of fibroblast, but it is also found in endothelial cells, myoepithelial 
cells, and neurons.  This poses quite a problem when attempting to study fibroblasts in vivo.  Of 
the known markers, the most specific marker appears to be the fibroblast-specific protein 1 
(FSP1). 
The results of the genomic analysis performed by Fukino et al. meant that there was a 
need for the ability to conditionally delete p53 and PTEN specifically in the stroma in order to 
establish what roles these two tumor suppressors might play in tumorigenesis and tumor 
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progression.  The answer to that demand and the subject of this thesis is a fibroblast specific Cre 
recombinase fusing the S400a4 promoter with the coding sequence of the P1 bacteriophage Cre 
recombinase. 
Cre recombinase of the P1 bacteriophage is a member of the integrase family of site-
specific recombinases.  Cre recombinase catalyzes recombination between two recognition sites 
called loxP sites (Nagy, 2000; Hamilton and Abremski, 1984).  The loxP site consists of 34 bp 
which would randomly occur only once in ever 1018 bp.  Considering that the mammalian 
genome is only 3 x 109 bp, it is very unlikely that the sequence would appear outside the phage 
genome, making it quite useful in mammalian genetics.  The consensus sequence consists of two 
13 bp palindromic sequences flanking and 8 bp spacer.  The spacer is asymmetric and thus 
confers an orientation to the loxP site.  One molecule of Cre recombinase recognizes each of the 
palindromic segments of the loxP site.  The recombinase molecules come together to form an 
active tetramer which recombines the DNA between the two loxP sites at the 8 bp spacer.  The 
recombination event can be one of inversion, deletion, or insertion depending upon the 
orientation and location of the loxP sites and requires no other co-factors or sequences to 
accomplish the recombination (Nagy, 2000; Voziyanov et al., 1999). 
 
Material and Methods 
Generation of FSP-cre transgenic mice.  
The transgene vector for Fsp1-Cre-BGH was created by inserting the BGH poly-A signal and the 
multiple cloning site of pcDNA3 (Invitrogen, Carlsbad, CA) into a modified pBluescript II 
plasmid backbone (Stratagene, La Jolla, CA).  The 3.1 kb Fsp1 gene promoter (S100a4) (Okada 
et al., 1995; Okada et al., 1998) extending 1.9 kb upstream of exon 1 to the end of intron 1 (1.2 
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kb) was long-range PCR amplified (Long Template System, Roche, Indianapolis) from 
C57BL/6NTac genomic DNA and cloned into the multiple cloning site of the vector. The Cre 
recombinase ORF from pMC-Cre (Gu et al., 1993) was PCR amplified and inserted between the 
Fsp1 promoter and the BGH poly-A signal. Cloning was completed by standard protocols and all 
fragments were verified by DNA sequencing. All microinjection constructs were injected into 
pronuclear stage FVB/N mouse embryos, as previously described (Overbeek et al., 1991; Taketo 
et al., 1991), after the Fsp1-Cre-BGH fragment was excised by Pac I (New England Biolabs, 
Beverly, MA) digestion and gel purified.  The same construct was used to obtain the 2nd 
generation animals, with the injections done at a later time. 
 
Southern Analysis 
3 µg of phenol/chloroform extracted DNA was digested in a 25µL volume using EcoR1 
endonuclease (New England Biolabs; 10:1) and separated on a 0.8% agarose gel.  The DNA 
fragments were denatured in the gel for 30min in a 0.5N sodium hydroxide/1.5mM sodium 
chloride solution and then transferred overnight to a Hybond-N+ membrane (Amersham) by the 
capillary method using the same solution. The probe was generated by a Pac1/ Apa1 double 
digest of the plasmid above.  The 4.3kb product, which contained the entire FSP-cre construct 
(minus the BGH region), was gel purified, extracted, quantified and labeled with P32 using the 
Rediprime system (Amersham).  The probe was hybridized to the membrane overnight and 
washed 2 times 15min with each a high (250mM sodium phosphate/1mM EDTA 2% SDS) and 
low (50mM sodium phosphate/1mM EDTA 1% SDS) stringency solutions. 
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Genotyping of Transgenic Mice 
DNA was isolated from mouse tail tips and genotyped by PCR analysis using the following 
primer sets: FSP-cre, forward (ATGCTTCTGTCCGTTTGCCG), reverse (CAATGCGATG-
CAATTTCCTC)-1082bp and Rosa26LoxP, common (AAAGTCGCTCTGAGTTGTTAT), wild-
type (GCGGGAGAAATGGATAT)-550bp, transgene (GCGAAGAGTTTGTCCTCAACC)-
260bp.  
 
Tissue Processing and X-gal Staining 
Tissue was excised and portions were processed for in situ X-gal staining.  Tissue was fixed 
directly in paraformaldehyde (2% PFA/0.2% glutaraldehyde in a 100 mM sodium phosphate 
buffer, pH=7.4) for 2 to 2.5 hours at 4oC, washed for 10 min twice in phosphate-buffered saline 
(PBS) and then stained in a 5-bromo-4-chloro-3-indolyl-D-galactopyranoside (X-gal) solution [4 
mM potassium ferricyanide (Sigma), 4mM potassium ferrocyanide (Sigma), 2 mM magnesium 
chloride (Sigma), 0.2% IGEPAL CA-630 (NP-40 substitute, Sigma), 0.1% sodium deoxycholic 
acid (Calbiochem) and 1 mg/mL X-gal (Gold Bio Technology, St. Louis, MO) in PBS for 18 
hours at RT protected from light.  X-gal-stained tissue was washed for 10 min twice with PBS 
and post-fixed in 10% neutral-buffered formalin (Richard Allen) for 48 hrs at RT.  Samples were 
then paraffin embedded, cut into 5 µm sections and counter-stained with nuclear fast red (NFR) 
and H&E. 
 
Immunohistochemistry 
Primary and secondary antibodies were diluted in DAKO diluent (DAKO) and applied in the 
following pairs: guinea pig anti-Cytokeratin 8/18 (1:250, RDI-PROGP11; Research 
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Diagnostics) with biotinylated donkey anti-guinea pig (1:500, Jackson Immunochemicals); and 
rabbit anti-α-SMA (1:100, BD Biosciences) with biotinylated sheep anti-rabbit (1:500, Jackson 
Immunochemicals)  5 µm sections were deparaffinized as follows.  The slides were heated in an 
oven at 60˚C for 10 minutes, then placed in xylene substitute twice for 5 minutes each.  They 
were rehydrated using two rinses in 100% ethanol for 3 minutes, soaked in 95% ethanol for 3 
minutes, and 70% ethanol for 3 additional minutes.  The slides were rinsed in water for 2 
minutes.  Endogenous peroxidases were quenched with 3% hydrogen peroxide for 3 minutes and 
rinsed in PBS for 5 minutes.  Sections were blocked with M.O.M. blocking reagent (Vector 
Labs) for 30min, rinsed, incubated with primary antibody for 30min, rinsed, incubated with a 
biotinylated secondary antibody for 15 minutes and rinsed.  Following the biotinylated secondary 
antibody use, the Vectastain ABC reagent (Vector Labs) was applied for 15 minutes and rinsed.  
Sections were incubated with the peroxidase substrate (DAB from Vector Labs) for until the 
desired staining was achieved.  The slides were rinsed in water for 5 minutes and dipped in 
Mayer’s Hematoxylin for 2 seconds to counterstain the tissue.  Sections were then rinsed in 
water for 5 minutes and dehydrated as follows:  2 times in 95% ethanol for 10 seconds each, 2 
times in 100% ethanol for 10 seconds each, 2 times in xylene substitute, and once in xylene.  The 
slides were then cover slipped using xylene-based mounting medium (Richard-Allan Scientific). 
 
Images 
Photographs of histological sections were taken with an Axio digital camera (Zeiss) mounted on 
the Axioskop microscope (Zeiss).  Whole mount photographs were taken with a Coolpix 5700 
digital camera (Nikon).  Image files were processed using Photoshop 7.0 (Adobe) or AxioVision 
4.3 software (Zeiss). 
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Transplantation of Mouse Mammary Glands   
All mice were 8 weeks old.  Cervical dislocation was used to euthanize the donor mouse which 
was then sterilized by emersion in 70% ethanol.  The mammary gland from either the fourth, 
fifth, ninth, or tenth position was removed.  The mammary gland was cut in half during the 
removal of the lymph node, and then placed in sterile saline.  The recipient mouse was sedated 
and anesthetized using isoflurane (Abbott Laboratories).  Hair was removed from the surgical 
area located on the interscapular region. The anesthetized mouse was moved into a sterile hood 
where the surgical area was sterilized using a Nolvastan scrub followed by 70% ethanol.  A 
subdermal pocket was made using curved scissors.  Application of a wound clip with an 
automatic feeding Michelle’s wound clip applicator followed the insertion of the donor gland 
into the pocket.  All dissection and operating tools were autoclaved and kept sterile through the 
procedure using 70% ethanol. 
 
Results 
 Through a series of fortunate events during the generation of the FSP-cre mice, two 
different transgenic alleles were created.  The first generation allele is the transgene expected to 
result from the recombination used to produce the FSP-cre.  The second generation is the 
combination of this transgene and a fibroblast specific transactivator.  The fortunate aspect is that 
the second generation FSP-cre is more specific than the first. 
 Southern analysis of the two fibroblast specific Cre recombinases easily distinguishes 
between the two.  After a partial digest with the EcoRI restriction enzyme, the endogenous FSP1 
gene appears as a very large segment of DNA approximately 10-11 kb in length.  Because the 
first generation transgene contains a single internal EcoRI restriction site, the appearance of two 
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bands other than the endogenous FSP1 reveals that a single copy of the FSP-cre transgene is 
present in the genome.  The shear size of the fragments in the second generation FSP-cre prevent 
knowing the exact number of copies inserted. 
 The visualization of FSP-cre expression requires the use of a conditional reporter.  For 
the purposes of the study, the Rosa26LoxP (Rosalox) transgene was selected.  This is a 
modification of the gene trap strain ROSA βgeo 26 in which a neo expression cassette has been 
inserted into the ROSA26 locus.  This neo cassette consists of a triple polyadenylation sequence 
added to the 3’ end of the coding region which is flanked by loxP sites and followed by a 
functional lacZ gene and another polyadenylation sequence.  In the absence of Cre recombinase, 
the lacZ gene will remain silent due to the presence of the triple polyadenylation sequence which 
prevents readthrough.  After the Cre recombinase-mediated excision of this silencer, the lacZ 
gene will be transcribed, translated, and used to visualize the expression of the FSP-cre. 
 In situ X-gal staining of FSP-cre embryos at E8.5 shows similar expression in the tails of 
both generations of the FSP-cre transgene.  During mouse development, somitogenesis begins on 
embryonic day eight (E8) with the epithelialization and further differentiation of mesenchymal 
cells as they migrate and separate from the posterior presomitic mesoderm.  The generation of 
the somites requires constant recruitment of cells to the paraxial mesoderm (Rossant and Tam, 
2002).  It is quite possible that fibroblastic characteristics are necessary for this process of 
mesenchymal migration, and thus the presence of the reporter.  The formation of the thymus 
begins on the twelfth day of development (E12) in the endoderm of the third and fourth 
pharyngeal pouches and the neighboring mesenchyme.  At this time, the thymic primordium 
buds into the mesenchyme and becomes surrounded by fibroblasts (Maronpot, 1999).  The 
expression of the rosalox reporter in the craniofacial region and around developing bone tissue is 
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also noteworthy as S100a4 (FSP1) is a negative regulator of mineralization of bone tissue and 
osteoblast differentiation (Duarte et al., 2003). 
 In the adult mammary gland, FSP-cre expression is not exclusive to the fibroblasts, but it 
is exclusive to the stroma.  Immunohistochemical staining verifies that epithelial cells positive 
for cytokeratin 8/18 are surrounded by cells expressing the reporter, but they themselves are not.  
All LacZ positive cells appear outside the thin ring of myoepithelial cells which form the outer 
boundary of the epithelial ducts.  The other parts of the stroma that appear to express the FSP-cre 
are endothelial cells and pericytes.  One key difference in the specificity of the two generations 
of FSP-cre is the positive staining of the lymph node in the first generation. 
 As stated before, fibroblasts are ubiquitous, and thus the characterization of FSP-cre 
expression must involve the entire mouse.  In the adult mouse, the main organs to take note of 
are the brain, pituitary gland, heart, spleen, thymus, and lungs.  The expression throughout the 
brain differs between the two FSP-cre recombinase constructs; however, most parts of the brain 
are affected in some way by both transgenes.  The polygonal cells of the pars intermedia are 
responsible for the staining observed in the pituitary gland.  The vasculature, as well as the 
fibroblasts, in the heart of the first generation FSP-cre mice stain positive for β-galactosidase 
expression; the second generation FSP-cre only affects the connective tissue around the heart.  
One of the most pronounced differences in expression between the two is in the spleen.  When a 
whole mount of the spleen from the first generation is X-gal stained in situ, the entire organ 
appears almost black.  A possible cause might be non-specific expression in a migratory 
inflammation and immune cell such as those which are prolific in the thymus considering that 
the spleen is a location for differentiation and maturation in hematopoesis.    The spleen of the 
second generation is largely normal but with a sparse amount of Cre-positive cells of 
 Page 12 of 18 
undetermined lineage.  The medulla of the thymus for the second generation FSP-cre and the 
cortex for both generations are free of lacZ staining.  The medulla of the first generation, 
however, has a significant amount of spotted staining.  The epithelial ducts of the salivary glands 
of both transgenic FSP-cre mice and the wild type express β-galactosidase, but these are 
epithelial cells that normally secrete digestive enzymes which break down sugars and should not 
be considered non-specific expression of the FSP-cre (For a complete overview of the localation 
of positive LacZ staining, refer to Table 1). 
 Genetic alterations in mammary epithelia has been done for years with little concern of 
affecting other aspects of the study because promoters like the mouse mammary tumor virus 
(MMTV) and whey acidic protein (WAP) promoters are specific for those highly differentiated 
cells.  This is not the case for fibroblasts.  The ubiquitous nature of fibroblasts that results in the 
expression of the FSP-cre throughout the body is a concern when attempting to study cancer.  
For example, the expression of FSP-cre in the pars intermedia of the pituitary gland poses quite a 
problem.  Any changes produced in the pituitary could cause imbalances in hormone levels that 
could affect the rate of tumor progression apart from the genetic activation of the 
microenvironment surrounding the tumor.  Another problem discovered through experimental 
trial is that test subjects can die from other complications before a mammary tumor actually 
forms.  In response to this concern, the task of transplantation has been undertaken.  By 
relocating the experimental tissue into a “normal” environment, all of these problems are 
avoided. 
 The transplantation of the fourth and ninth mammary glands of a mouse carrying the 
FSP-cre transgene into the interscapular region of wild-type mouse was used to determine the 
 Page 13 of 18 
practicality of this approach to address the issue.  The in situ β-galactosidase assay confirmed 
that transplanted tissue can survive for up to sixteen weeks.  
Discussion 
 From the very outset of this project, the goal was clear—to establish a way to genetically 
alter the stroma as to mimic the changes previously observed in the tumor microenvironment.  
One of those changes would be an increased deposition of ECM molecules such as is the case of 
carcinoma-associated fibroblasts (Sadlonova et al., 2005; Kunz-Schughart, 2002).  Preliminary 
results of a study using the second generation FSP-cre transgene to delete the tumor suppressor 
PTEN show a marked increase in the deposition of collagen in the transplanted tissue 
(unpublished, Trimboli).  The type of collagen and the affect that this has on the progression of 
the tumor has yet to be determined, but this finding is encouraging. 
 The implementation of a fibroblast-specific Cre recombinase could end up playing a vital 
role in future studies of tumor-stroma interactions; however, this approach to altering the stroma 
has its own limitations to be considered as well.  The deletion of the target genes occurs very 
early in development and is unable to be used in studies requiring great control over the moment 
of initiation of an activated stroma.  The next step is to establish a reliable inducible fibroblast-
specific Cre recombinase system that would allow development to remain completely unaffected.  
A reverse transactivator would be a good choice because a response could be seen almost 
immediately; whereas, with a tet-off system, it is possible that tetracycline might remain in the 
tissue for an unknown period of time because of the surrounding adipose tissue.  Another 
disadvantage of a tet-off system is that when dealing with deletion, if the mice fail to receive the 
appropriate amount of tetracycline at any moment, the gene is permanently lost from those cells 
that express the FSP-cre only briefly, as well as their descendent cells. 
 Page 14 of 18 
 Overall, the value of the FSP-cre system is the ability to study the affects of an activated 
stroma in vivo.  While cell lines like those of CAFs can be used to study communication between 
epithelial cells and fibroblasts in vitro, the ability to prove that in vitro results are actually the 
case in vivo will always be important.  Even more important is the ability to transfer that 
knowledge into clinical practice.  By elucidating the power of the stroma in the process of 
tumorigenesis and tumor progression, the prognosis and diagnosis for many patients could be 
made more precisely because the genetic alterations observed in the stroma which affect the rate 
of progression could be considered.  With a less optimistic prognosis, a risky and more 
aggressive treatment might be used compared to a good prognosis.  Understanding the role the 
tumor microenvironment plays in the initiation and growth of a tumor will have a direct affect on 
the treatment of the cancer patient. 
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Fig. 1. Plasmid Illustration and Southern Analysis of the FSP-cre Founder Mice.  
(a) Schematic representation of the generated FSP-cre plasmid.  The locations of 
the PCR primers used for genotyping (horizontal arrows) and restriction sites for 
(vertical arrows) are indicated.  (b) Southern analysis of the FSP-cre insertion into 
the mouse genome.  The endogenous Fsp1 is present in all tail DNA samples 
(~10-11kb)  Lane 1: FSP-cre plasmid.  Lane 2: size marker.  Lane 3+: tail DNA.
Fig. 2. Embryonic Expression Pattern Using FSP-cre/Rosaloxp System.  The utilization of 
X-gal staining to visualize FSP-cre expression in first generation FSP-cre (a,d), the 
second generation FSP-cre (b,e), and the wild-type (c,f) embryos at E9.5 (a-c) and E13.5 
(d-f).  The developing thymus in the E13.5 embryos is indicated by an arrow (d,e).  
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Fig. 3. Fibroblast Specificity in the Adult Mouse Mammary Gland. The visualization of the 
reporter gene Rosaloxp to determine FSP-cre function and specificity in the first generation 
FSP-cre (a-c), the second generation FSP-cre (d-f), and the wild-type (g,h).
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Fig. 4. In situ LacZ staining of the major organs.
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Fig. 6. Length of survival of stroma after transplantation.  FSP-cre/Rosalox
labeled 10th generation FVB/N mouse mammary gland tissue was transplanted 
to a wild-type 10th generation FVB/N host.  Transplanted tissue is removed after 
(a) 2 weeks, (b) 4 weeks, (c) 8 weeks, and (d) 16 weeks.  LacZ staining 
confirms the survival of the transplanted stroma for the designated period of 
time.
ab
Fig. 7. Mason’s trichrome staining of transplanted mammary glands 7 weeks after 
transplantation.  The blue-staining material is collagen.  (a) MMTV-c-neu without 
fibroblast-specific deletion of PTEN.  (b) MMTV-c-neu with fibroblast-specific deletion 
of PTEN.
Table 1. Location of Positive LacZ Staining
Organ Site of Positive LacZ Staining Organ Site of Positive LacZ Staining
Brain 1st gen:
•Majority of brain
2nd gen:
•Pons, thalamus, cerebellum, cerebrum, 
median eminence, area postrema
Liver 1st gen:
•Around portal triads
2nd gen:
•The positive staining is at a site of 
extramedullary hematopoiesis
Lung 1st gen:
•Vasculature 
2nd gen:
•Near bronchial tubes
Gall Bladder 1st gen:
•Vasculature
2nd gen:
•Vasculature
Thymus 1st gen:
•Spotted staining in medulla
2nd gen:
•None
Pancreas 1st gen:
•Vasculature
2nd gen:
•Vasculature
Pituitary Gland 1st gen:
•Pars intermedia
2nd gen:
•Pars intermedia
Kidney 1st gen:
•Vasculature
•Collecting ducts
2nd gen:
•Proximal tubular epithelium 
•Interlobar vasculature
Spleen 1st gen:
•Multiple cell types throughout
2nd gen:
•Sparse expression in cells of 
undetermined lineage
Ovary 1st gen:
•Cells of the copora lutea
•Theca interna around antral follicles
2nd gen:
•Cells of the copora lutea
•Theca interna antral follicles
Heart 1st gen:
•Vasculature
2nd gen:
•None
Uterus 1st gen:
•Throughout endometrium & 
myometriium
2nd gen:
•Uterine glands
Salivary Gland 1st gen:
•Epithelial ducts (background)
2nd gen:
•Epithelial ducts (background)
Urinary Bladder 1st gen:
•Vasculature within the lamina propria
and surrounding muscle
2nd gen:
•Vasculature within the lamina propria
and surrounding muscle
Eye 1st gen:
•Inner nuclear layer of retina
•Spotted exp. in ganglion
•Epithelia surrounding lens
2nd gen:
•Inner nuclear layer of retina
•Epithelia surrounding lens
Cecum 1st gen:
•Lamina propria portion of mucosa
2nd gen:
•The surface of epithelium; most likely, 
remains from material being excreted.
Muscle 1st gen:
•Vasculature
2nd gen:
•Vasculature
Stomach 1st gen:
•Epithelium of forestomach
2nd gen:
•Submucosa and muscular tunic
